About GCE GroupThe GCE Group is Europe's leading gas-equipment company and organized according to four business areas: Cutting and Welding, Medical, High-Purity and Process Applications. Backed by Argan Capital Advisors LLP, a leading independent private equity fund focused on acquiring European mid-market companies, GCE's product portfolio corresponds to a large variety of applications, from simple pressure regulators and blowpipes for cutting and welding to sophisticated gas supply systems for medical and electronics industry applications. GCE's portfolio includes a large number of brands such as Butbro, Charledave, DruVa, Mediline, Mujelli, Propaline, Rhona and Sabre Medical, which are leaders within their own respective regional markets and applications. The GCE Group has grown rapidly since its establishment and is leading the restructuring of the European gas-equipment industry through mergers and acquisitions. The group currently employs approximately 1,100 people. About Dehaier Medical Systems Ltd. Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD ( Italy), Welch Allyn ( USA), HEYER ( Germany), Timesco (UK), eVent Medical (US) and JMS ( Japan). Dehaier's technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn Forward-looking Statements This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the exclusive distribution agreement of EASE II. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.